Distribution and Antifungal Susceptibility Profiles of Candida Species Isolated from Patients at a Romanian Tertiary Care Hospital
Open Access
- 10 November 2026
- journal article
- research article
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (11) , 845
Abstract
This study aimed to evaluate the species distribution and antifungal susceptibility profiles in Candida spp. isolates over a 17-month period in a tertiary care hospital from Bucharest, Romania. A total of 108 isolates retrieved from inpatients and outpatients were identified by MALDI-TOF and tested for susceptibility against a YO10 nine-agent panel provided by SensiTitreTM. Among the selection criteria for isolates were the sample’s origin and laboratory procedures used for antifungal testing. The MICs were interpreted according to the current CLSI breakpoints (M27M44S) and current ECVs (M57S). From a total of 92 Candida isolates with defined susceptibility breakpoints, 77 isolates (83.69%) were susceptible to fluconazole, and additionally, 11 N. glabratus (11/12, one isolate resistant) were evaluated as susceptible-dose dependent (SDD). C. albicans was the most frequently isolated species, accounting for 56.48% of all strains (61/108 isolates). Susceptibility to fluconazole in this subgroup was 86.88% (53/61 isolates). Non-albicans species were represented by a total of 47 isolates (43 with established breakpoints). The fluconazole susceptibility rate was 83.87% (26/31 isolates), notably lower than C. albicans isolates, and it was calculated by excluding N. glabratus isolates. The finding of fluconazole-resistant C. parapsilosis sensu stricto in blood cultures (3 of 6 isolates) is clinically relevant. Although this is a small exploratory comparison, the result is in line with the Southern-European signal (ECMM Candida III). Echinocandins resistance rate (Anidulafungin, Micafungin, Caspofungin) was low (2.85%, 3/105 strains with defined susceptibility cut-offs) but not alternatively documented, with MICs ranging from 1 to 4 μg/mL in two C. albicans and one C. tropicalis isolate. This study underscores the importance of tracking local epidemiological data and antifungal susceptibility patterns given the diversity of patient groups in large medical units.Keywords
Funding Information
- the University of Medicine and Pharmacy Carol Davila
This publication has 31 references indexed in Scilit:
- Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASMThe Lancet Infectious Diseases, 2025
- Insights from Three Pan-European Multicentre Studies on Invasive Candida Infections and Outlook to ECMM Candida IVMycopathologia, 2024
- European candidaemia is characterised by notable differential epidemiology and susceptibility pattern: Results from the ECMM Candida III studyJournal of Infection, 2023
- Invasive candidiasis: current clinical challenges and unmet needs in adult populationsJournal of Antimicrobial Chemotherapy, 2023
- Deciphering the epidemiology of invasive candidiasis in the intensive care unit: is it possible?Infection, 2021
- Candidemia and Invasive CandidiasisInfectious Disease Clinics of North America, 2021
- ECMM CandiReg—A ready to use platform for outbreaks and epidemiological studiesMycoses, 2019
- Invasive Fungal Infection in Romania: Changing Incidence and Epidemiology During Six Years of Surveillance in a Tertiary HospitalMycopathologia, 2018
- Epidemiology and reporting of candidaemia in Belgium: a multi-centre studyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Risk factors for candidemia in non-neutropenic critical patients in ColombiaMedicina Intensiva (English Edition), 2016